{ "week": "2026-W35", "label": "Week 35 \u2014 August 30\u20135, 2026", "week_start": "2026-08-30", "generated": "2026-08-31", "stats": { "total_entries": 1180, "new_this_week": 49, "compounds_represented": 5 }, "by_compound": { "psilocybin": [ { "id": "fd3c36b14c94e628ee062a4b29352361ce8595dd1df6fefbb1e25c26b5d3ec49", "title": "A randomized crossover trial comparing the acute physiological and psychological effects of botanical formulations of oral psilocybin, oral psilocin, and sublingual psilocin.", "compound": "psilocybin", "type": "phase_2", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-08-29", "abstract": "Psilocybin, a serotonergic psychedelic found in hallucinogenic mushrooms, is metabolized to psilocin, the compound responsible for its psychoactive effects. Psilocybin has demonstrated therapeutic potential for neuropsychiatric conditions.\u2026", "outcome_summary": null, "doi": "10.1177/02698811261478603", "url": "https://pubmed.ncbi.nlm.nih.gov/42668404/", "source": "PubMed", "first_seen": "2026-08-31", "relevance": { "relevant": true, "reason": "Human study of psilocybin for neuropsychiatric conditions.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-31" } }, { "id": "f93e06d916cfd63d1830e7d7dc3dc80cdb64a31c612ff43a23c2048601f7038d", "title": "Oregon's state-regulated psilocybin services: Early real-world safety signals.", "compound": "psilocybin", "type": "phase_2", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-08-28", "abstract": null, "outcome_summary": null, "doi": "10.1177/02698811261481171", "url": "https://pubmed.ncbi.nlm.nih.gov/42665360/", "source": "PubMed", "first_seen": "2026-08-31", "relevance": { "relevant": true, "reason": "Real-world safety of psilocybin services in Oregon.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-31" } }, { "id": "91d4c41d71762105a796b7d64e877bd56f39e25c34829af70b13f4ec8690f761", "title": "Development of a Physiologically Based Pharmacokinetic/Pharmacodynamic Model of Psilocybin/Psilocin from Psilocybe cubensis (Magic Mushroom) in Treatment-Resistant Depression.", "compound": "psilocybin", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-08-28", "abstract": "Psilocybin, a prodrug that converts to psilocin, exerts psychedelic and antidepressant effects primarily through serotonin 2A (5-HT2A) receptor agonism.\u2026", "outcome_summary": null, "doi": "10.1007/s13318-026-01033-x", "url": "https://pubmed.ncbi.nlm.nih.gov/42663926/", "source": "PubMed", "first_seen": "2026-08-31", "relevance": { "relevant": true, "reason": "Psilocybin for treatment-resistant depression.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-31" } }, { "id": "a7694ea37e55f70d43cbb7dadb97ee2d53b92156f72a62e7385574c4d85aa450", "title": "AMCP Market Insights: Optimizing managed care approaches to treatment-resistant depression.", "compound": "psilocybin", "type": "meta_analysis", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-09-01", "abstract": "Treatment-resistant depression (TRD) is a subset of major depressive disorder (MDD) most commonly defined as failure to respond to 2 or more antidepressant regimens despite adequate dose, duration, and adherence to treatment.\u2026", "outcome_summary": null, "doi": "10.18553/jmcp.2026.32.9-a.s1", "url": "https://pubmed.ncbi.nlm.nih.gov/42658027/", "source": "PubMed", "first_seen": "2026-08-31", "relevance": { "relevant": true, "reason": "Treatment-resistant depression is a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-31" } }, { "id": "0b1e33390f347f891996edf7857e67502c6d8ee13392ea5457330cc4a7991dce", "title": "Psychedelic integration beyond the verbal: participatory-imaginal processing as a hypothesis-generating therapeutic framework.", "compound": "psilocybin", "type": "phase_2", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-01-01", "abstract": "Psilocybin therapy in patients with cancer commonly produces vivid embodied and imaginal experiences that resist verbal description, yet most current integration approaches rely primarily on cognitive and verbal processing.\u2026", "outcome_summary": null, "doi": "10.3389/fpsyt.2026.1895181", "url": "https://pubmed.ncbi.nlm.nih.gov/42656547/", "source": "PubMed", "first_seen": "2026-08-31", "relevance": { "relevant": true, "reason": "Psilocybin therapy for cancer patients, focusing on integration.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-31" } }, { "id": "96112693eccdb76f0f94e6d8075427c2c17ca447008685188bc55829cb803a96", "title": "Psychedelic Safety and Clinical Outcomes Across Exposure Patterns: A Structured Narrative Review.", "compound": "psilocybin", "type": "meta_analysis", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-08-14", "abstract": "Clinical trials and naturalistic studies describe psychedelics under markedly different exposure conditions.\u2026", "outcome_summary": null, "doi": "10.3390/life16081338", "url": "https://pubmed.ncbi.nlm.nih.gov/42653026/", "source": "PubMed", "first_seen": "2026-08-31", "relevance": { "relevant": true, "reason": "Review of clinical trials and naturalistic studies of psychedelics.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-31" } }, { "id": "8ed179b58c7e27068e4dee69fe932d561b565dc60c51fee97596ec3f98dbeef4", "title": "Psilocybin-Assisted Therapy in Psychiatry: A Narrative Clinical Review of Mechanisms, Therapeutic Applications, and Emerging Evidence (2025-2026).", "compound": "psilocybin", "type": "meta_analysis", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-08-12", "abstract": "Background/Objectives: Psilocybin-assisted therapy has progressed from early proof-of-concept work to a substantially expanded evidence base, with four pivotal studies published in 2025-2026 that were not incorporated into earlier reviews.\u2026", "outcome_summary": null, "doi": "10.3390/jcm15166228", "url": "https://pubmed.ncbi.nlm.nih.gov/42652632/", "source": "PubMed", "first_seen": "2026-08-31", "relevance": { "relevant": true, "reason": "Review of psilocybin therapy for psychiatric conditions.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-31" } }, { "id": "f4c06d4c41b9fc692cd4cbdbec3893984d73f111e9fc9afef87062f291d24f46", "title": "Pilot study comparing the effects of high dose THC to high dose psilocybin and placebo in the set and setting of a classic psychedelic therapy session.", "compound": "psilocybin", "type": "phase_2", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-08-27", "abstract": "Delta-9-tetrahydrocannabinol (\u03949-THC) has been reported to evoke psychedelic-like experiences at high doses in some individuals. However, the doses of \u03949-THC that occasion such effects and the phenomenology of these experiences are poorly understood.\u2026", "outcome_summary": null, "doi": "10.1007/s00213-026-07138-0", "url": "https://pubmed.ncbi.nlm.nih.gov/42649324/", "source": "PubMed", "first_seen": "2026-08-31", "relevance": { "relevant": true, "reason": "Compares THC and psilocybin in a psychedelic therapy context.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-31" } }, { "id": "a2762d57069e3205dab213d0ef8de93e5f5fa3bf291f2b8d5fa205182421165a", "title": "Next-Generation Pharmacotherapies for Unipolar Mood Disorders: A Leading Article on Phase II/III Drug Development Across Diverse Mechanisms.", "compound": "psilocybin", "type": "meta_analysis", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-08-26", "abstract": "Despite the wide prevalence of mood disorders globally, there is a substantial unmet need for effective, mechanistically distinct treatments.\u2026", "outcome_summary": null, "doi": "10.1007/s40263-026-01330-8", "url": "https://pubmed.ncbi.nlm.nih.gov/42645703/", "source": "PubMed", "first_seen": "2026-08-31", "relevance": { "relevant": true, "reason": "Discusses drug development for mood disorders, a key psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-31" } }, { "id": "8d50bea2f13f455dc619b7ddf806f7c8d1a7f75d8726c5ff933dbf9900502989", "title": "Toward an Optimal Framework for Psilocybin Regulation: A Comparison of State Regulatory Approaches Across Key Dimensions.", "compound": "psilocybin", "type": "phase_2", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-08-25", "abstract": "Over the past decade, psilocybin has shifted from being viewed as a recreational drug to one that has demonstrated therapeutic potential in the treatment of several mental health conditions.\u2026", "outcome_summary": null, "doi": "10.1080/01947648.2026.2713478", "url": "https://pubmed.ncbi.nlm.nih.gov/42640727/", "source": "PubMed", "first_seen": "2026-08-31", "relevance": { "relevant": true, "reason": "Psilocybin regulation and therapeutic potential for mental health.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-31" } }, { "id": "485d9b754747bd5d1aa0c0ec07375ee079f6fb264624da62e7ce7a50fb7c4f15", "title": "The Effects of Psilocybin on Social Connectedness", "compound": "psilocybin", "type": "phase_1", "institution": "Yale University", "condition": "other", "sample_size": 51, "status": "recruiting", "date": "2026-08-31", "abstract": "The study is a randomized, double-blind, placebo-controlled, expectancy-controlled, mechanistic trial.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT07693153", "source": "ClinicalTrials.gov", "first_seen": "2026-08-31", "relevance": { "relevant": true, "reason": "Psilocybin for social connectedness in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-31" } }, { "id": "5d779ad991b53ecf046e99316d8d8d1fe40c74730db44bc56ab37e216beca9ef", "title": "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder", "compound": "psilocybin", "type": "phase_3", "institution": "Cybin IRL Limited", "condition": "depression", "sample_size": 330, "status": "recruiting", "date": "2025-12-10", "abstract": "The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in patients with MDD.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT06793397", "source": "ClinicalTrials.gov", "first_seen": "2026-08-31", "relevance": { "relevant": true, "reason": "Human study of psilocin analog for major depressive disorder.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-31" } }, { "id": "92d09b8b75f129c8ae20427c545109626fa173f44474888df6967be2488096eb", "title": "Beyond the Self and Back: Neuropharmacological Mechanisms Underlying the Dissolution of the Self", "compound": "psilocybin", "type": "observational", "institution": "University of Zurich", "condition": "other", "sample_size": 140, "status": "completed", "date": "2013-10-01", "abstract": "The aim of the study is to identify neural signatures, behavioral and phenomenological expressions of self-related processes including: sense of agency, semantic distinction between self and other, selflessness (altruism), social agency, embodied self (interoception), perceptual functioning of dissolved self including hallucinations and crossmodal processing, and finally the mystical type dissolution of the self.", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT03736980", "source": "ClinicalTrials.gov", "first_seen": "2026-08-31", "relevance": { "relevant": true, "reason": "Investigates self-related processes and phenomenology of psychedelic dissolution.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-31" } }, { "id": "a9c06174539d5da8d6f32a9206c18ca9208e720e5b7e5293c1bde4300a10047a", "title": "MB-PAT for Demoralization in Advanced Cancer ('PAT-MIND') Trial", "compound": "psilocybin", "type": "phase_2", "institution": "University of Calgary", "condition": "other", "sample_size": 60, "status": "recruiting", "date": "2026-10-30", "abstract": "This pilot clinical trial will study psilocybin-assisted therapy for adults with advanced cancer who are experiencing demoralization, existential distress, or related psychological concerns.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT07791901", "source": "ClinicalTrials.gov", "first_seen": "2026-08-31", "relevance": { "relevant": true, "reason": "Psilocybin for existential distress in advanced cancer patients.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-31" } }, { "id": "12a066d2ca41275c0e2e24bc5bb69d96e7bf4ab7fb31f7e4b0f1eefb5abda986", "title": "Healing in Community: Reflections on Racial Trauma and Plant Medicine in Oaxaca", "compound": "psilocybin", "type": "news", "institution": null, "condition": "other", "sample_size": null, "status": "other", "date": "2026-08-24", "abstract": "

In November 2025, I helped organize a small retreat in Oaxaca, Mexico for a group of racialized psychotherapists.\u2026", "outcome_summary": "A retreat was organized in Oaxaca, Mexico, for racialized psychotherapists to explore whether psilocybin mushrooms could support healing from racial trauma when approached with cultural responsibility. The event aimed to create space for practitioners to reflect on their experiences and receive care, while respecting the cultural context of plant medicine practices.", "doi": null, "url": "https://chacruna.net/healing-in-community-reflections-on-racial-trauma-and-plant-medicine-in-oaxaca/", "source": "Chacruna Institute", "first_seen": "2026-08-31", "relevance": { "relevant": true, "reason": "Psilocybin for racial trauma in psychotherapists.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-31" } }, { "id": "a88020d8bcd1ade898836b926b7a14fbb465141a2c510039101f6700ee95b2d1", "title": "Weekly Psychedelic Policy Briefing: August 14, 2026", "compound": "psilocybin", "type": "phase_3", "institution": "U.S. Department of Veterans Affairs (VA)", "condition": "depression", "sample_size": null, "status": "recruiting", "date": "2026-08-14", "abstract": "

In this week\u2019s Psychedelic Policy Briefing, investigative journalist Jack Gorsline digs into the details of developments that could impact research into psychedelic-assisted therapies including multi-site VA clinical trials.\u2026", "outcome_summary": "The U.S. Department of Veterans Affairs (VA) has launched PIVOT, a five-site clinical trial evaluating the therapeutic use of psilocybin (COMP360) for veterans with treatment-resistant depression. The trial aims to establish safety parameters and dosing protocols, potentially influencing future insurance reimbursement for psilocybin therapy.", "doi": null, "url": "https://www.lucid.news/weekly-psychedelic-policy-briefing-august-14-2026/", "source": "Lucid News", "first_seen": "2026-08-31", "relevance": { "relevant": true, "reason": "VA trial of psilocybin for veterans with depression", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-31" } }, { "id": "b7cbcaa869ec85221a53efcf1f676a49489ee678c24485949c93e49509836db8", "title": "A real-world study of Oregon's nonmedical psilocybin program shows promise", "compound": "psilocybin", "type": "observational", "institution": "Oregon Health & Science University", "condition": "other", "sample_size": 350, "status": "published", "date": "2026-08-19", "abstract": "Much of the recent momentum around psychedelics has centered on running drug development trials, with the aim of eventually winning approval from the Food and Drug Administration so that psilocybin, LSD and other substances can be used to treat mental health conditions.\u2026", "outcome_summary": "A study of nearly 350 people who took psilocybin in Oregon's regulated program found that most participants described their experience as beneficial, with over half ranking it among the most meaningful experiences of their lives. The data also suggests the program was overall quite safe, with a very small number reporting serious adverse reactions.", "doi": "10.1001/jamanetworkopen.2026.xxxx", "url": "https://www.npr.org/2026/08/19/nx-s1-5936443/oregon-psilocybin-ptsd-depression-anxiety", "source": "General News", "first_seen": "2026-08-31", "relevance": { "relevant": true, "reason": "Real-world study of Oregon's psilocybin program shows promise.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-31" } }, { "id": "f1c1d9bebfb2db743d842830f5311b952121e542580e9aab91522f28911630b2", "title": "Psilocybin FDA Priority Review 2026: Compass Pathways Depression, PTSD Approval?", "compound": "psilocybin", "type": "regulatory", "institution": "Compass Pathways", "condition": "depression", "sample_size": null, "status": "approved", "date": "2026-06-17", "abstract": "On April 24, 2026, the U.S.\u2026", "outcome_summary": "Compass Pathways' COMP360 psilocybin therapy has received FDA Breakthrough Therapy Designation for treatment-resistant depression and PTSD, indicating potential for expedited review and approval.", "doi": null, "url": "https://www.medicaldaily.com/psilocybin-fda-priority-review-2026-compass-pathways-depression-ptsd-approval-475666", "source": "General News", "first_seen": "2026-08-31", "relevance": { "relevant": true, "reason": "Psilocybin therapy for depression and PTSD, FDA review.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-31" } } ], "mdma": [ { "id": "d6cfcd31fb706f7018c0a9a0a0a773275d194a7941d1e264169b428a429fd49d", "title": "MAPS Responds to Report of Progress for MDMA-assisted therapy for PTSD with FDA", "compound": "mdma", "type": "regulatory", "institution": "Multidisciplinary Association for Psychedelic Studies (MAPS)", "condition": "PTSD", "sample_size": null, "status": "approved", "date": "2026-08-10", "abstract": "WASHINGTON, Aug.\u2026", "outcome_summary": "MAPS responded to a report that Resilient Pharmaceuticals resubmitted its new drug application (NDA) for MDMA-assisted therapy for PTSD to the FDA. This follows a Complete Response Letter issued in August 2024, which recommended additional research. The new guidance from the FDA addresses areas central to the previous recommendations.", "doi": null, "url": "https://www.globenewswire.com/news-release/2026/08/10/3342145/0/en/maps-responds-to-report-of-progress-for-mdma-assisted-therapy-for-ptsd-with-fda.html", "source": "General News", "first_seen": "2026-08-31", "relevance": { "relevant": true, "reason": "MDMA-assisted therapy for PTSD with FDA regulatory news.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-31" } } ], "ketamine": [ { "id": "1125158576c0279c0f3042583ad894891cd18a9fa12be81ad1f9d73aa86274a1", "title": "An Integrative Model of Ketamine-Induced Memory Dysfunction: From Synapse to Circuit in Clinical Context.", "compound": "ketamine", "type": "meta_analysis", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-08-30", "abstract": "Ketamine presents a modern pharmacological paradox, acting as both a rapid-acting antidepressant and a drug of abuse with significant cognitive consequences.\u2026", "outcome_summary": null, "doi": "10.1016/j.neuro.2026.103558", "url": "https://pubmed.ncbi.nlm.nih.gov/42669313/", "source": "PubMed", "first_seen": "2026-08-31" }, { "id": "5a86e8bf754edfb2271782a5fa0d3f67880d2c8dfbac7e2a969260dc37f3fec3", "title": "The role of BDNF promoter VI in mediating protective effects of prophylactic (R,S)-ketamine.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-08-29", "abstract": "Brain-derived neurotrophic factor (BDNF) exon VI promoter is implicated in mediating activity-induced synthesis of hippocampal BDNF. BDNF is implicated in (R,S)-ketamine's antidepressant effects, but its role in (R,S)-ketamine-mediated prophylaxis is unknown.\u2026", "outcome_summary": null, "doi": "10.1038/s41386-026-02536-6", "url": "https://pubmed.ncbi.nlm.nih.gov/42668318/", "source": "PubMed", "first_seen": "2026-08-31", "relevance": { "relevant": true, "reason": "Investigational treatment for depression, mechanism of action.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-31" } }, { "id": "537741c072191bfca4a48d7937e093dbdfbb6d87ae331064856d4369bef7f09a", "title": "Esketamine-based treatment, depression-specific metacognitive training, and their combination in treatment-resistant depression: 6-month trajectories of depressive symptoms and rumination in a multicenter observational study.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-08-29", "abstract": "Treatment-resistant depression (TRD) remains a highly burdensome clinical condition, and improvement in depressive severity does not necessarily imply parallel modification of maladaptive cognitive-affective processes such as rumination.\u2026", "outcome_summary": null, "doi": "10.1007/s00406-026-02361-4", "url": "https://pubmed.ncbi.nlm.nih.gov/42667415/", "source": "PubMed", "first_seen": "2026-08-31", "relevance": { "relevant": true, "reason": "Esketamine for treatment-resistant depression in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-31" } }, { "id": "efaf949b278ead58fcf4ee50a8a53f37fe74fca4b7f260f368acbc2733ec4a3d", "title": "Therapeutic Prospects of Ketamine for Cataplexy in Narcolepsy Type 1: Evidence from a Human Case and a Murine Model.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-08-28", "abstract": "Narcolepsy type 1 is characterized by cataplexy, for which current treatments targeting monoaminergic, histaminergic, and GABAergic pathways may be ineffective or poorly tolerated.\u2026", "outcome_summary": null, "doi": "10.1002/ana.78343", "url": "https://pubmed.ncbi.nlm.nih.gov/42663325/", "source": "PubMed", "first_seen": "2026-08-31", "relevance": { "relevant": true, "reason": "Ketamine for narcolepsy type 1, a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-31" } }, { "id": "390065961a9862bbfb8cb46a5b60f5d56b0998a0cccf62203bcca8a540baf9da", "title": "Psychedelics in psychiatry: comparative effectiveness, implementation, commercialization and safety lessons learned from intranasal esketamine.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-08-28", "abstract": null, "outcome_summary": null, "doi": "10.1080/14740338.2026.2726227", "url": "https://pubmed.ncbi.nlm.nih.gov/42663266/", "source": "PubMed", "first_seen": "2026-08-31", "relevance": { "relevant": true, "reason": "Intranasal esketamine for psychiatric treatment, implementation, and safety.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-31" } }, { "id": "94cd51cd522c3a8ee68fd767b481bf8c7f4cf27d573e4b3f4501c047043fbbf5", "title": "Erratum to \"Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study\" [European Neuropsychopharmacology 107 (2026) 112801].", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-08-27", "abstract": null, "outcome_summary": null, "doi": "10.1016/j.euroneuro.2026.113860", "url": "https://pubmed.ncbi.nlm.nih.gov/42659716/", "source": "PubMed", "first_seen": "2026-08-31", "relevance": { "relevant": true, "reason": "Esketamine for treatment-resistant depression is a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-31" } }, { "id": "6f49ae209458a86afbcca62939e4e068dcd4d8a84c211f1f684e2fa03ef1c8a4", "title": "Perfusion Index and Hemodynamic Responses During Propofol Induction with Fentanyl or Ketamine-Lidocaine Adjuncts: A Prospective Randomized Pilot Clinical Study.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-07-25", "abstract": "Background and Objectives: Hemodynamic instability during anesthesia induction and endotracheal intubation remains a clinically important concern. Low-dose ketamine and intravenous lidocaine may provide complementary effects that improve cardiovascular stability and peripheral perfusion.\u2026", "outcome_summary": null, "doi": "10.3390/medicina62081443", "url": "https://pubmed.ncbi.nlm.nih.gov/42654340/", "source": "PubMed", "first_seen": "2026-08-31" }, { "id": "ba23726c28d6fcfb1dbbe2896891cf6740d8a474316b5bba4cb2960667c72242", "title": "Efficacy and tolerability of ketamine in moderate to severe obsessive-compulsive disorder: a systematic review.", "compound": "ketamine", "type": "meta_analysis", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-08-27", "abstract": "Approximately 40-60% of patients with obsessive-compulsive disorder (OCD) fail to respond to standard serotonergic and behavioral therapies. This systematic review evaluates the efficacy, durability, and safety of ketamine, a glutamate modulator, for moderate to severe OCD.\u2026", "outcome_summary": null, "doi": "10.1007/s00213-026-07155-z", "url": "https://pubmed.ncbi.nlm.nih.gov/42649323/", "source": "PubMed", "first_seen": "2026-08-31", "relevance": { "relevant": true, "reason": "Ketamine for obsessive-compulsive disorder (OCD) is a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-31" } }, { "id": "58e7df3ab96ff3db612778476209bb45bffb3414327ce73f487bb054e8409d6b", "title": "Complex regional pain syndrome and amputation.", "compound": "ketamine", "type": "meta_analysis", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-08-25", "abstract": "Complex regional pain syndrome (CRPS) is a debilitating poorly understood condition with unpredictable course and heterogeneous therapeutic responses. Early, coordinated multidisciplinary management, including psychological and psychiatric support, is essential.\u2026", "outcome_summary": null, "doi": "10.1016/j.medcli.2026.107577", "url": "https://pubmed.ncbi.nlm.nih.gov/42641373/", "source": "PubMed", "first_seen": "2026-08-31", "relevance": { "relevant": true, "reason": "CRPS is a chronic pain condition, a relevant treatment target.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-31" } }, { "id": "8ad54fb5de1e9b82f9a9076f2b0b2004180da876217b4ca8cea9adeae82ec2bd", "title": "Case report of S-ketamine as treatment option for suicidal ideation and treatment-resistant depression in adolescents with early-onset psychosis.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-08-25", "abstract": "Depressive symptoms and suicidality are highly prevalent in adolescents with early-onset psychosis (EOP) and often remain refractory to standard treatment.\u2026", "outcome_summary": null, "doi": "10.1007/s40211-026-00587-1", "url": "https://pubmed.ncbi.nlm.nih.gov/42640420/", "source": "PubMed", "first_seen": "2026-08-31", "relevance": { "relevant": true, "reason": "S-ketamine for treatment-resistant depression and suicidal ideation in adolescents.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-31" } }, { "id": "ee7f9b795154f3c55f96ec8bb7b4844de468915ebf4f53f8c5b91a64b11e568f", "title": "A Single-Day Intravenous Ketamine Infusions for Fibromyalgia, a Large Retrospective Study with a Long-Term Assessment.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-01-01", "abstract": "Fibromyalgia is a complex chronic neurosensory disorder that affects approximately 2% of the population. Ketamine acts as a non-competitive antagonist of the N-methyl-D-aspartate receptor, which plays a crucial role in nociceptive hypersensitivity.\u2026", "outcome_summary": null, "doi": "10.2147/JPR.S629157", "url": "https://pubmed.ncbi.nlm.nih.gov/42634681/", "source": "PubMed", "first_seen": "2026-08-31", "relevance": { "relevant": true, "reason": "Ketamine for chronic pain (fibromyalgia) in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-31" } }, { "id": "cc4378bc999a50c42eee215f4f60e91839a9553b57d3a490f06197d774b735f4", "title": "Modern Management of Complex Regional Pain Syndrome: A Practical Evidence-Based Review for Hand and Upper Extremity Surgeons.", "compound": "ketamine", "type": "meta_analysis", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-07-01", "abstract": "Complex regional pain syndrome (CRPS) is a debilitating pain disorder that most commonly develops following fractures, surgery, peripheral nerve injury, or other trauma to an extremity.\u2026", "outcome_summary": null, "doi": "10.7759/cureus.113271", "url": "https://pubmed.ncbi.nlm.nih.gov/42634670/", "source": "PubMed", "first_seen": "2026-08-31", "relevance": { "relevant": true, "reason": "Covers treatment of chronic pain (CRPS).", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-31" } }, { "id": "3b757256548a21da1c2f67316afc6f4a76380cb593d2fca2fdd895795c323469", "title": "Blood Levels of Ketamine in Patients Using Topical Application of 10% Ketamine Gel for Neuropathic Pain", "compound": "ketamine", "type": "observational", "institution": "London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's", "condition": "other", "sample_size": 15, "status": "active", "date": "2011-06-01", "abstract": "The purpose of this research study is to measure how much, if any, ketamine is absorbed into the blood stream after ketamine gel is applied to the skin.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT01385904", "source": "ClinicalTrials.gov", "first_seen": "2026-08-31", "relevance": { "relevant": true, "reason": "Topical ketamine for neuropathic pain in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-31" } }, { "id": "16ef98f0882f85b61204e6d5f77847f34a4c38df58d9f8d5ecbfa4003cc51291", "title": "Effects Of PF-02545920 On Ketamine-Induced Abnormal Prefrontal Brain Response To Associative Learning In Healthy Subjects", "compound": "ketamine", "type": "phase_1", "institution": "Pfizer", "condition": "other", "sample_size": 4, "status": "completed", "date": "2011-04-01", "abstract": "To evaluate whether PF-02545920 reduces the effects of ketamine on brain activation during causal learning as measured by fMRI compared to placebo in healthy human subjects, and to evaluate whether behavioral measures of abnormal causal learning under ketamine are reduced by treatment with PF 02545920.", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT01244880", "source": "ClinicalTrials.gov", "first_seen": "2026-08-31", "relevance": { "relevant": true, "reason": "Human study on ketamine's effects on brain response", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-31" } }, { "id": "9011b9fd1dd1fcf623cfcee2c5bbe68492be44952d7c5f7cd289d756512a8b01", "title": "Double-Blind Trial of Ketamine Therapy Plus or Minus Naltrexone in Treatment Resistant Depression (TRD)", "compound": "ketamine", "type": "phase_1", "institution": "Stanford University", "condition": "depression", "sample_size": 16, "status": "completed", "date": "2016-09-01", "abstract": "The primary objective is to determine if the opioid properties of ketamine are responsible for its antidepressant effects. Since naltrexone can block opiate actions, the investigators will determine if naltrexone can effectively block ketamine's effects.", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT02911597", "source": "ClinicalTrials.gov", "first_seen": "2026-08-31", "relevance": { "relevant": true, "reason": "Ketamine for treatment resistant depression.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-31" } }, { "id": "26c0d92c3559fcd9a6e96d2ce58754cb3bc878742eb281c8c8aa0058c477dd34", "title": "Cognitive Therapy to Sustain the Antidepressant Effects of Intravenous Ketamine in Treatment-resistant Depression", "compound": "ketamine", "type": "observational", "institution": "Yale University", "condition": "depression", "sample_size": 28, "status": "completed", "date": "2017-01-01", "abstract": "The goals of this study are: 1) to investigate the efficacy of combining ketamine with intensive cognitive behavioral therapy (CBT) to sustain the antidepressant effects of ketamine; and 2) to determine ketamine's delayed effects on learning and memory, and to explore the relationship between any ketamine-induced changes in learning and memory and duration of antidepressant efficacy, with and without CBT augmentation.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT03027362", "source": "ClinicalTrials.gov", "first_seen": "2026-08-31", "relevance": { "relevant": true, "reason": "Ketamine for treatment-resistant depression with cognitive therapy.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-31" } }, { "id": "5308d813b7f83b5c6fba74f150524b63e034b33a2a713bf09fb88e23835f41d8", "title": "Low-dose S-Ketamine and Postpartum Depression in Parturients With Prenatal Depression", "compound": "ketamine", "type": "observational", "institution": "Peking University First Hospital", "condition": "depression", "sample_size": 364, "status": "completed", "date": "2020-06-19", "abstract": "Prenatal depression is an important risk factor of postpartum depression. Low-dose ketamine has been used for depression treatment. As a stereoisomer of ketamine, s-ketamine has similar effects to ketamine in anti-depression.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT03927378", "source": "ClinicalTrials.gov", "first_seen": "2026-08-31", "relevance": { "relevant": true, "reason": "Low-dose S-ketamine for postpartum depression treatment.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-31" } }, { "id": "e7db02f5b8434c970b2422f003f54ad0d6cd262b8253f1cb491ddc589d411f5a", "title": "Intranasal (NAS) Ketamine for Cancer Pain", "compound": "ketamine", "type": "phase_1", "institution": "Emory University", "condition": "other", "sample_size": 10, "status": "completed", "date": "2017-07-25", "abstract": "The main purpose of this study is to determine the safety, feasibility, and utility of intranasal (NAS) ketamine in persistent uncontrolled cancer related pain.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT03146806", "source": "ClinicalTrials.gov", "first_seen": "2026-08-31", "relevance": { "relevant": true, "reason": "Intranasal ketamine for chronic cancer pain in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-31" } }, { "id": "0aa53cca69503d717e6af3d4dba5932a93b356fc2fb945ab154714edd837188f", "title": "Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression", "compound": "ketamine", "type": "phase_2", "institution": "National Institute of Mental Health (NIMH)", "condition": "depression", "sample_size": 50, "status": "recruiting", "date": "2024-11-06", "abstract": "Major depressive disorder (MDD) is a serious mental illness that can put people at risk of self-harm and death. Many drugs are used to treat MDD, but it can take a long time for them to be effective.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT06511908", "source": "ClinicalTrials.gov", "first_seen": "2026-08-31", "relevance": { "relevant": true, "reason": "Antidepressant effects of a compound in treatment-resistant depression.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-31" } }, { "id": "1234fa9b08b6303e542ec04e23d794085e20bc92b214b071a845375b417f805a", "title": "Randomized Controlled Trial of Intranasal Ketamine vs. Intranasal Midazolam in Individuals With OCD", "compound": "ketamine", "type": "phase_2", "institution": "New York State Psychiatric Institute", "condition": "OCD", "sample_size": 2, "status": "completed", "date": "2014-09-01", "abstract": "Obsessive-compulsive disorder (OCD) is a common illness that causes significant distress and impairment. Currently, serotonin reuptake inhibitors (SRIs) are the only medications that are FDA-approved to treat OCD.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT02206776", "source": "ClinicalTrials.gov", "first_seen": "2026-08-31", "relevance": { "relevant": true, "reason": "OCD is a psychiatric indication, ketamine is the treatment.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-31" } }, { "id": "b814b06b6c2d990bcd324df4110ee24231d60cab8a526936d4c4d782e4be4b8f", "title": "Ketamine + Cognitive Training for Suicidality in the Medical Setting", "compound": "ketamine", "type": "observational", "institution": "Rebecca Price", "condition": "other", "sample_size": 200, "status": "active", "date": "2021-03-15", "abstract": "This project seeks to identify the acute and longer-term impact of a single dose of intravenous ketamine among suicidal patients referred for psychiatric consultation/liaison in the medical inpatient setting.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT04578938", "source": "ClinicalTrials.gov", "first_seen": "2026-08-31", "relevance": { "relevant": true, "reason": "Ketamine for suicidality in psychiatric patients.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-31" } }, { "id": "58103b9b9fbf79782c852715ff17e5f9e35f260b3d615109719e96618e0d6a7a", "title": "The Role of Ketamine and Dexmedetomidine in Opioid-Sparing Analgesia", "compound": "ketamine", "type": "observational", "institution": "Fayoum University Hospital", "condition": "other", "sample_size": 90, "status": "completed", "date": "2022-08-05", "abstract": "Optimal multimodal opioid-sparing analgesic technique is considered as one of the most important Enhanced recovery pathways (ERPs) or enhanced recovery after surgery (ERAS) interventions that mitigate the undesirable effects of surgical stress response.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT05474183", "source": "ClinicalTrials.gov", "first_seen": "2026-08-31" }, { "id": "5f74991e06ed317c94c79654341fd5a88dcd52d5d28f7b3ad178c4d8ace0c966", "title": "Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Elderly Japanese, and Healthy Younger Adult Japanese Subjects", "compound": "ketamine", "type": "phase_1", "institution": "Janssen Research & Development, LLC", "condition": "other", "sample_size": 37, "status": "completed", "date": "2016-08-09", "abstract": "The purpose of this study is to compare the pharmacokinetics, safety, and tolerability of intranasally administered esketamine in elderly Japanese subjects and healthy younger adult Japanese subjects.", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT02857777", "source": "ClinicalTrials.gov", "first_seen": "2026-08-31", "relevance": { "relevant": true, "reason": "Human study on esketamine pharmacokinetics, safety, and tolerability.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-31" } }, { "id": "e943b56bf622d63e38a5201fa8d77cf2f59fbe1186d427797ddda0455b2c7a01", "title": "Is Ketamine for Depression Moving Too Fast on Weak Data?", "compound": "ketamine", "type": "phase_3", "institution": "Trinity College Dublin", "condition": "depression", "sample_size": 62, "status": "published", "date": "2026-05-15", "abstract": "0162 Credits Lead image: Generative AI by Open AI Medscape Medical News \u00a9 2026 WebMD, LLC Send comments and news tips to news@medscape.net. Cite this: Attride D. Is Ketamine for Depression Moving Too Fast on Weak Data? - Medscape - May 15, 2026.\u2026", "outcome_summary": "A randomized controlled trial at Trinity College Dublin found that adding ketamine to usual inpatient care offered no additional benefit compared to a psychoactive placebo for depression symptoms. Meta-analyses suggest short-term antidepressant effects, but concerns remain about study limitations and safety.", "doi": "2840552", "url": "https://www.medscape.com/viewarticle/ketamine-depression-moving-too-fast-weak-data-2026a1000fr0", "source": "General News", "first_seen": "2026-08-31", "relevance": { "relevant": true, "reason": "RCT on ketamine for depression with safety concerns.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-31" } } ], "ibogaine": [ { "id": "3171f9607755dfb5d4265ab4dd16861baf7edfa6d931432f899da4438cc57535", "title": "University of Miami\u2019s Gift", "compound": "ibogaine", "type": "regulatory", "institution": "University of Miami", "condition": "other", "sample_size": null, "status": "approved", "date": "2026-08-25", "abstract": "

Washington, D.C., August 25, 2026 \u2014 The Multidisciplinary Association for Psychedelic Studies (MAPS)has welcomed the announcement that the University of Miami has gifted the federal government its 1994 ibogaine Investigational New Drug (IND) application.

An IND is the authorization issued by the U.S.\u2026", "outcome_summary": "MAPS welcomed the University of Miami's gift of its 1994 ibogaine Investigational New Drug (IND) application to the federal government. MAPS provided initial funding for this research in the 1990s and has since published its own Ibogaine Investigator's Brochure to consolidate decades of data.", "doi": null, "url": "https://maps.org/2026/08/25/university-of-miamis-gift/", "source": "MAPS.org", "first_seen": "2026-08-31", "relevance": { "relevant": true, "reason": "MAPS received an IND application for ibogaine research.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-31" } } ], "other": [ { "id": "f07d4bb73c8cc3ab1b09192e8bfb5aa3a4df4cf6ecd4a0dbd31ddaa541d2add8", "title": "Oncology Providers' Perspectives on Psychedelic-Assisted Therapy.", "compound": "other", "type": "phase_2", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-08-28", "abstract": "PurposeDespite most psychedelic substances remaining Schedule I, clinical research exploring psychedelic-assisted therapy (PAT) in oncology is expanding.\u2026", "outcome_summary": null, "doi": "10.1177/10499091261483604", "url": "https://pubmed.ncbi.nlm.nih.gov/42661611/", "source": "PubMed", "first_seen": "2026-08-31", "relevance": { "relevant": true, "reason": "Psychedelic-assisted therapy for oncology patients is relevant.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-31" } }, { "id": "0d210e90283473304a61847de4b1a8f00abe19369cae8e5eec68ee18a6bb89a3", "title": "ATLAS-1: Advanced Trial for Longitudinal Assessment in Salma 1", "compound": "other", "type": "observational", "institution": "Salma Health, Inc.", "condition": "depression", "sample_size": 5000, "status": "recruiting", "date": "2026-03-25", "abstract": "This study will evaluate the feasibility and clinical utility of developing predictive models of treatment response for patients with depressed mood using multimodal clinical data collected in real-world clinical settings.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT07528014", "source": "ClinicalTrials.gov", "first_seen": "2026-08-31", "relevance": { "relevant": true, "reason": "Depression is a psychiatric indication for psychedelic treatment.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-31" } }, { "id": "972c4c534101e5eef79407308b7baaa26cb9d4730e73f5c61b7b3f8a2106f163", "title": "Queering Psychedelics 2026", "compound": "other", "type": "news", "institution": "Chacruna", "condition": "other", "sample_size": null, "status": "other", "date": "2026-08-25", "abstract": "

Celebrate 10 years of Chacruna and our groundbreaking book \u201cQueering Psychedelics\u201d with Bia Labate, Clancy Cavnar, and Paulina Valamiel in a vibrant community conversation honoring queer voices, Indigenous reciprocity, and a more inclusive psychedelic future.

Buy Tickets

About the event

As part of Chacruna’s 10th anniversary celebration, Bia Labate and Clancy Cavnar join Paulina Valamiel for a conversation on why psychedelics cannot be separated from social justice.\u2026", "outcome_summary": "This event celebrates Chacruna's 10th anniversary and the book 'Queering Psychedelics' with a community conversation focusing on queer voices, Indigenous reciprocity, and inclusivity in the psychedelic future. It highlights the intersection of psychedelics with social justice, gender, and sexuality, featuring speakers like Bia Labate, Clancy Cavnar, and Paulina Valamiel.", "doi": null, "url": "https://chacruna.net/queering-psychedelics-2026/", "source": "Chacruna Institute", "first_seen": "2026-08-31", "relevance": { "relevant": true, "reason": "Focuses on social justice and inclusivity in psychedelics.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-31" } }, { "id": "2f5944d2c6985f1385ecfe86fa2eb0da31cc2d81de1b4abef22e4e77d9a487c5", "title": "Conspirituality: Seeking Hidden Truths in the Post-Truth Era", "compound": "other", "type": "news", "institution": "University of Humanistic Studies", "condition": "other", "sample_size": null, "status": "published", "date": "2026-08-24", "abstract": "

Do you wish you got into this event for free? Become a Chacruna member and receive free or discounted access to all Community Forums, Courses, Workshops, and more!\u2026", "outcome_summary": "This article discusses the intersection of spirituality and conspiracy thinking, exploring how psychedelic and contemplative practices can influence the perception of truth and the potential for self-sealing beliefs. It examines epistemic discernment and critiques conspirituality without replicating its logic.", "doi": null, "url": "https://chacruna.net/conspirituality-seeking-hidden-truths-in-the-post-truth-era/", "source": "Chacruna Institute", "first_seen": "2026-08-31", "relevance": { "relevant": true, "reason": "Discusses psychedelics' influence on truth perception and beliefs.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-31" } }, { "id": "afc19e715a2de075f05fc583941201ce3b31ea5c356d217292917e2c4f9e7d56", "title": "FDA moves to fast-track review of psilocybin and methylone for mental health", "compound": "other", "type": "regulatory", "institution": "FDA", "condition": "other", "sample_size": null, "status": "approved", "date": "2026-04-24", "abstract": "\u201cWe are accelerating the research, approval, and responsible access to promising mental health treatments \u2013 including psychedelic therapies like ibogaine \u2013 to confront our nation\u2019s mental health crisis head-on, especially for our veterans,\u201d US Health and Human Services Secretary Robert F.\u2026", "outcome_summary": "The FDA issued national priority vouchers to three companies studying psychedelic-based medicines: psilocybin for treatment-resistant depression and major depressive disorder, and methylone for PTSD. These vouchers aim to fast-track the review process for these drugs.", "doi": null, "url": "https://www.cnn.com/2026/04/24/health/fda-psychedelic-drugs-priority-vouchers", "source": "General News", "first_seen": "2026-08-31", "relevance": { "relevant": true, "reason": "FDA fast-track review of psilocybin and methylone for mental health", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-31" } } ] } }